SIGHT — Gensight Biologics SA Income Statement
0.000.00%
Last trade - 00:00- €33.81m
- €50.46m
- €1.50m
Annual income statement for Gensight Biologics SA, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 4.39 | 5.28 | 2.58 | 1.27 | 1.5 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 29.3 | 33.4 | 30.4 | 31 | 17.3 |
| Operating Profit | -24.9 | -28.1 | -27.8 | -29.7 | -15.8 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -34 | -28.6 | -27.6 | -26.2 | -14 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -34 | -28.6 | -27.6 | -26.2 | -14 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -34 | -28.6 | -27.6 | -26.2 | -14 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -34 | -28.6 | -27.6 | -26.2 | -14 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.968 | -0.634 | -0.596 | -0.543 | -0.146 |
| Dividends per Share |